Skip to main content
Back
PEN logo

Penumbra, Inc.

Data quality: 100%
PEN
NYSE Healthcare Medical - Devices
$335.56
▼ $0.29 (-0.09%)
Mkt Cap: 13.17B
Day Range
$334.83 $337.81
52-Week Range
$221.26 $362.41
Volume
573,398
50D / 200D Avg
$341.27 / $283.75
Prev Close
$335.85

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 74.1 0.4
P/B 9.2 2.9
ROE % 13.8 3.7
Net Margin % 12.7 3.9
Rev Growth 5Y % 17.1 10.0
D/E 0.2 0.2

Analyst Price Target

Hold
$371.92 +10.8%
Low: $349.00 High: $388.00
Forward P/E
66.8
Forward EPS
$5.02
EPS Growth (est.)
+0.0%
Est. Revenue
1.6 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2029 $9.25
$8.93 – $9.57
2.3 B 2
FY2028 $7.60
$7.03 – $8.91
2 B 4
FY2027 $6.37
$5.47 – $6.90
1.8 B 11

Key Takeaways

Revenue grew 17.06% annually over 5 years — strong growth
Earnings grew 1168.11% over the past year
ROE of 13.78% — decent returns on equity
Debt/Equity of 0.15 — conservative balance sheet
Generating 174.93M in free cash flow
P/E of 74.11 — premium valuation

Growth

Revenue Growth (5Y)
17.06%
Revenue (1Y)17.50%
Earnings (1Y)1168.11%
FCF Growth (3Y)45.95%

Quality

Return on Equity
13.78%
ROIC8.62%
Net Margin12.66%
Op. Margin13.48%

Safety

Debt / Equity
0.15
Current Ratio6.64
Interest Coverage0.00

Valuation

P/E Ratio
74.11
P/B Ratio9.22
EV/EBITDA69.76
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17.50% Revenue Growth (3Y) 15.15%
Earnings Growth (1Y) 1168.11% Earnings Growth (3Y) 39.77%
Revenue Growth (5Y) 17.06% Earnings Growth (5Y) 140.81%
Profitability
Revenue (TTM) 1.40B Net Income (TTM) 177.69M
ROE 13.78% ROA 9.73%
Gross Margin 67.14% Operating Margin 13.48%
Net Margin 12.66% Free Cash Flow (TTM) 174.93M
ROIC 8.62% FCF Growth (3Y) 45.95%
Safety
Debt / Equity 0.15 Current Ratio 6.64
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 74.11 P/B Ratio 9.22
P/S Ratio 9.38 PEG Ratio 0.06
EV/EBITDA 69.76 Dividend Yield 0.00%
Market Cap 13.17B Enterprise Value 13.20B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.40B 1.19B 1.06B 847.13M 747.59M
Net Income 177.69M 14.01M 90.95M -2.00M 5.28M
EPS (Diluted) 4.52 0.36 2.32 -0.05 0.14
Gross Profit 942.44M 755.00M 682.64M 535.21M 475.38M
Operating Income 189.25M 9.28M 73.55M 6.08M -7.50M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.83B 1.53B 1.56B 1.37B 1.24B
Total Liabilities 398.92M 382.25M 377.36M 372.03M 290.32M
Shareholders' Equity 1.43B 1.15B 1.18B 998.86M 953.93M
Total Debt 219.70M 223.39M 234.34M 235.77M 173.55M
Cash & Equivalents 186.90M 324.40M 167.49M 69.86M 59.38M
Current Assets 1.22B 951.13M 915.40M 755.70M 681.47M
Current Liabilities 183.13M 158.35M 151.14M 144.93M 123.20M